MBX Biosciences, Inc. (MBX)
30.99
+1.12
(+3.75%)
USD |
NASDAQ |
Jun 10, 16:00
31.00
+0.01
(+0.03%)
After-Hours: 18:51
MBX Biosciences Enterprise Value : 981.51M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 981.51M |
| June 08, 2026 | 940.12M |
| June 05, 2026 | 1.001B |
| June 04, 2026 | 1.031B |
| June 03, 2026 | 990.07M |
| June 02, 2026 | 1.021B |
| June 01, 2026 | 1.019B |
| May 29, 2026 | 1.058B |
| May 28, 2026 | 1.078B |
| May 27, 2026 | 1.078B |
| May 26, 2026 | 1.072B |
| May 22, 2026 | 1.077B |
| May 21, 2026 | 1.074B |
| May 20, 2026 | 1.057B |
| May 19, 2026 | 1.007B |
| May 18, 2026 | 1.035B |
| May 15, 2026 | 1.105B |
| May 14, 2026 | 1.244B |
| May 13, 2026 | 1.345B |
| May 12, 2026 | 1.321B |
| May 11, 2026 | 1.468B |
| May 08, 2026 | 1.510B |
| May 07, 2026 | 1.213B |
| May 06, 2026 | 1.089B |
| May 05, 2026 | 969.46M |
| Date | Value |
|---|---|
| May 04, 2026 | 961.85M |
| May 01, 2026 | 977.23M |
| April 30, 2026 | 998.16M |
| April 29, 2026 | 921.57M |
| April 28, 2026 | 942.03M |
| April 27, 2026 | 1.081B |
| April 24, 2026 | 1.081B |
| April 23, 2026 | 1.149B |
| April 22, 2026 | 1.158B |
| April 21, 2026 | 1.142B |
| April 20, 2026 | 1.168B |
| April 17, 2026 | 1.167B |
| April 16, 2026 | 1.141B |
| April 15, 2026 | 1.129B |
| April 14, 2026 | 1.121B |
| April 13, 2026 | 1.121B |
| April 10, 2026 | 1.035B |
| April 09, 2026 | 1.124B |
| April 08, 2026 | 1.067B |
| April 07, 2026 | 996.73M |
| April 06, 2026 | 1.050B |
| April 02, 2026 | 1.130B |
| April 01, 2026 | 1.097B |
| March 31, 2026 | 980.56M |
| March 30, 2026 | 905.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 2.146B |
| Corcept Therapeutics, Inc. | 7.988B |
| Assertio Holdings, Inc. | 119.95M |
| Veru, Inc. | 21.82M |
| Johnson & Johnson | 603.30B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.52M |
| Total Expenses (Quarterly) | 23.52M |
| EPS Diluted (Quarterly) | -0.5049 |
| Earnings Yield | -7.13% |
| Normalized Earnings Yield | -7.128 |